Sponsor

Stanley Medical Research Institute

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Stanley Medical Research Institute appears in 100 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials100
Recruiting shown2
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

60 shown
Role of Minocycline in First Episode PsychosisNCT00916461 · lead sponsor · 2006-05-01
COMPLETED
Antidepressant Therapy for Bipolar II Major DepressionNCT00641927 · lead sponsor · 2002-04-01
COMPLETED
Acetazolamide for Treatment Resistant SchizophreniaNCT04887792 · collaborator · 2022-02-01
RECRUITING
Cromoglicate Adjunctive Therapy for Outpatients With SchizophreniaNCT03794076 · collaborator · 2019-04-01
RECRUITING
Luteolin for the Treatment of People With SchizophreniaNCT05204407 · collaborator · 2022-06-13
COMPLETED
Estradiol as add-on to AntipsychoticsNCT04093518 · collaborator · 2019-12-02
UNKNOWN
Adjunctive Withania Somnifera (Ashwagandha) for Persistent Symptoms in People With SchizophreniaNCT03437668 · collaborator · 2018-12-01
TERMINATED
Aspirin in Young Psychotic PatientsNCT02685748 · collaborator · 2017-07-20
COMPLETED
Sodium Butyrate For Improving Cognitive Function In SchizophreniaNCT03010865 · collaborator · 2017-06-01
WITHDRAWN
A 6-month Study to Evaluate Sulforaphane add-on Effects in Treatment of SchizophreniaNCT02880462 · collaborator · 2016-12-26
COMPLETED
Siltuximab in SchizophreniaNCT02796859 · collaborator · 2016-05-01
UNKNOWN
Sodium Butyrate For Improving Cognitive Function In SchizophreniaNCT02654405 · collaborator · 2016-04-01
WITHDRAWN
Estradiol Patch as add-on to Antipsychotics in Patients With Schizophrenia, Schizoaffective or Schizophreniform DisorderNCT03848234 · collaborator · 2015-12-04
COMPLETED
Carnosine and Cognitive Training in SchizophreniaNCT02686697 · collaborator · 2015-12-01
COMPLETED
Study of Immunotherapy in Autoantibody Positive PsychosisNCT02449746 · collaborator · 2015-08-01
COMPLETED
A Proof of Concept Study of Intravenous Sodium Nitroprusside in Adults With Symptomatic SchizophreniaNCT02164981 · collaborator · 2015-05-01
COMPLETED
Targeted Vitamin D Treatment of Schizophrenia-Associated HyperprolinemiaNCT02197286 · collaborator · 2015-02-01
WITHDRAWN
Schizophrenia TreAtment With electRic Transcranial StimulationNCT02535676 · collaborator · 2014-11-01
COMPLETED
Exenatide Weekly Injections as an Adjunctive Treatment in Patients With SchizophreniaNCT02417142 · collaborator · 2014-09-01
COMPLETED
Treatment of Schizophrenia With L-tetrahydropalmatine (l-THP): a Novel Dopamine Antagonist With Anti-inflammatory and Antiprotozoal ActivityNCT02118610 · collaborator · 2014-09-01
COMPLETED
Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in SchizophreniaNCT02104752 · collaborator · 2014-07-01
COMPLETED
A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase SchizophreniaNCT02008773 · collaborator · 2014-03-26
COMPLETED
Famotidine in SchizophreniaNCT01946295 · collaborator · 2014-03-01
UNKNOWN
Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of SchizophreniaNCT02034474 · collaborator · 2014-02-01
COMPLETED
Simvastatin Addition for Patients With Recent-onset SchizophreniaNCT01999309 · collaborator · 2013-10-01
COMPLETED
TDCS for Auditory Hallucinations in SchizophreniaNCT01898299 · collaborator · 2013-05-01
COMPLETED
Pilot Trial of Valproate as Adjunctive Treatment for Toxoplasma Gondii Infection in Early Course SchizophreniaNCT02011750 · collaborator · 2013-04-01
COMPLETED
Minocycline for SchizophreniaNCT01809158 · collaborator · 2013-04-01
COMPLETED
Valacyclovir Augmentation for Cognitive and Functional Remediation in SchizophreniaNCT01794897 · collaborator · 2013-02-01
COMPLETED
Probiotics to Prevent Relapse After Hospitalization for ManiaNCT01731171 · collaborator · 2012-11-01
COMPLETED
Kuvan in People With Schizophrenia and Schizoaffective DisorderNCT01706965 · collaborator · 2012-10-01
COMPLETED
Minocycline Augmentation in SchizophreniaNCT01561742 · collaborator · 2012-02-01
UNKNOWN
Raloxifene as an Adjuvant Treatment of the Negative Symptoms of Schizophrenia in Post-menopausal WomenNCT01573637 · collaborator · 2011-07-01
COMPLETED
The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage SchizophreniaNCT01339858 · collaborator · 2011-05-01
COMPLETED
To Rescue Cognition With ValaciclovirNCT01364792 · collaborator · 2011-04-01
COMPLETED
Randomized Double Blind Placebo Control Study in Patients with SchizophreniaNCT01602029 · collaborator · 2010-08-01
COMPLETED
Double-Blind Trial of a Probiotic Supplement to Reduce the Symptoms of SchizophreniaNCT01242371 · collaborator · 2010-08-01
COMPLETED
Effects of Pravastatin on Cholesterol, Inflammation and Cognition in SchizophreniaNCT01082588 · collaborator · 2010-06-01
COMPLETED
Study Using Pregnenolone to Treat Bipolar DepressionNCT01409096 · collaborator · 2010-03-01
COMPLETED
Cannabidiol Treatment of Cognitive Dysfunction in SchizophreniaNCT00588731 · collaborator · 2009-02-01
COMPLETED
Melatonin Treatment for Tardive Dyskinesia in SchizophreniaNCT01391390 · collaborator · 2008-09-01
COMPLETED
Artemisinin With Risperidone for First-Episode and Drug-Naive SchizophreniaNCT01391403 · collaborator · 2008-09-01
COMPLETED
Artemisinin to Reduce The Symptoms of SchizophreniaNCT00753506 · collaborator · 2008-08-01
COMPLETED
Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight GainNCT00709202 · collaborator · 2008-07-01
COMPLETED
Study to Demonstrate Cognitive Enhancing Effects of BF2.649NCT00690274 · collaborator · 2008-06-01
COMPLETED
Oxytocin Add on Study for Stable Schizophrenic PatientsNCT00506909 · collaborator · 2008-03-01
TERMINATED
Add-on Simvastatin in Schizophrenia TrialNCT00605995 · collaborator · 2008-02-01
TERMINATED
Low Field Magnetic Stimulation in Mood Disorders Using the LFMS DeviceNCT00578383 · collaborator · 2007-11-01
COMPLETED
The Effects of Varenicline on Cognitive Function in Patients With SchizophreniaNCT00523445 · collaborator · 2007-09-01
COMPLETED
An Exploratory Open Label Study of Adjunctive L-lysine Treatment in Patients With SchizophreniaNCT00996242 · collaborator · 2007-09-01
COMPLETED
Randomized Clinical Trial of Intensive Computer-based Cognitive Remediation in Recent-onset SchizophreniaNCT00694889 · collaborator · 2007-08-01
COMPLETED
Systematic Evaluation of Antiviral Medication in SchizophreniaNCT00514449 · collaborator · 2007-06-01
COMPLETED
Magnetic Seizure Therapy (MST) for Severe Mood DisorderNCT00488748 · collaborator · 2007-06-01
COMPLETED
Efficacy of Pregnenolone in Patients With SchizophreniaNCT00615511 · collaborator · 2007-06-01
COMPLETED
Varenicline Adjunctive Treatment in SchizophreniaNCT00492349 · collaborator · 2007-05-01
COMPLETED
Rasagiline in the Treatment of Persistent Negative Symptoms of SchizophreniaNCT00492336 · collaborator · 2007-01-01
COMPLETED
A Study of Taurine in Patients With First-episode Psychosis Receiving Antipsychotic TreatmentNCT00420823 · collaborator · 2007-01-01
COMPLETED
Effects of Pentazocine Versus Lorazepam on Manic SymptomsNCT00431184 · collaborator · 2007-01-01
COMPLETED
L-Theanine in the Management of SchizophreniaNCT00372151 · collaborator · 2006-10-01
COMPLETED
A Pilot Study of Citicoline add-on Therapy in Patients With Bipolar Disorder or Major Depressive Disorder and Amphetamine Abuse or DependenceNCT00377299 · collaborator · 2006-10-01
COMPLETED

Drugs studied in this sponsor's trials

60 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Stanley Medical Research Institute as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
placebo37
estradiol4
minocycline3
simvastatin3
glycine2
memantine2
placebo Oral Tablet2
pravastatin2
placebo RxCUI 8375 · Lead sponsor in 1 linked trial(s) · 2 currently recruiting 37 trials estradiol RxCUI 4083 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 4 trials minocycline RxCUI 6980 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 3 trials simvastatin RxCUI 36567 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 3 trials glycine RxCUI 4919 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 2 trials memantine RxCUI 6719 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 2 trials placebo Oral Tablet RxCUI 375221 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 2 trials pravastatin RxCUI 42463 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 2 trials pregnenolone RxCUI 114052 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 2 trials raloxifene RxCUI 72143 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 2 trials risperidone RxCUI 35636 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 2 trials serine, D- RxCUI 1742747 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 2 trials valacyclovir RxCUI 73645 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 2 trials acetazolamide RxCUI 167 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 1 trial acetylcysteine RxCUI 197 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial artemisinin RxCUI 2367409 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial aspirin RxCUI 1191 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial atomoxetine RxCUI 38400 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial betahistine RxCUI 1511 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial cannabidiol RxCUI 2045371 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial carnosine RxCUI 1362697 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial celecoxib RxCUI 140587 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial cholecalciferol RxCUI 2418 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial citicoline RxCUI 997602 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

collaborator98
lead sponsor2
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.